Slide 1: ArcticZymes Technologies
A ArcticZymes Technologies
Slide 2: Agenda
Agenda 1 Highlights – Q3 2022 2 Business Update 3 Financials 4 Outlook 2022 and Beyond
Slide 3: Highlights
Highlights
Slide 4: Highlights Q3 2022
Highlights Q3 2022 Growth trend continues Growth continues AZT enters Achieved growth in discussions with a in Biomanufacturing quarterly sales select group of following the 29.3 MNOK international pandemic companies Achieved EBITDA expression of performance several RNA 2.8 MNOK enzyme prototypes 4
Slide 5: Business Update
Business Update
Slide 6: Business Updates: Biomanufacturing and Molecular Tools
Business Updates Commercial Biomanufacturing Molecular Tools ✓ Quarterly sales 15.9 MNOK (26% growth) ✓ Quarterly sales 13.4 MNOK (2% growth) ✓ Accounts for 54% of total Q3 sales ✓ Accounts for 46% of total Q3 sales ✓ Upturn in sales following pandemic continues ✓ Research and Diagnostics contributi
Slide 7: Business Updates: Geographical Sales Contribution
Business Updates Commercial Geographical Sales Contribution Americas EMEA APAC 2021 39 % 48 % 13 % Q1 Americas EMEA APAC 2022 41 % 46 % 13 % Q2 Americas EMEA AP. 2022 39 % 52 % 9% Q3 Americas EMEA APAC 2022 50 % 37 % 13 % • Seasonal effects most prominent in the EMEA • Extended customer holidays fol
Slide 8: Product portfolio and innovation pipeline
Product portfolio and innovation pipeline Bulk, OEM and customised – to meet customers needs IsoPol® RNA RNA Capping SAP Cod UNG Endonucleases Exonucleases Polymerases SAN HQ M-SAN HQ SAN HQ 2.0 Polymerases Enzymes Reverse Taq DNA Pyrophosphat RNase 2-O-Meythl- Other Proteinases Ligases Transcriptas
Slide 9: Business Updates: Strategic Growth Initiatives
Business Updates Strategic Growth Initiatives AZT remains committed to execute on its strategic growth initiatives Organic growth Ongoing recruitment drive to strengthen the organisation cross functionally Open-mindset with respect to location Inorganic growth Intensive activity towards M&A M&A proc
Slide 10: Financials
Financials
Slide 11: Sales
Sales Continues to grow Sales 35 Biomanufacturing Sales increase of 16 % compared to same Molecular Tools 30 quarter last year Achieved 29.3 MNOK (25.2 MNOK) 25 Biomanufacturing (SAN) Sales in MNOK 20 15.9 MNOK (12.6 MNOK) 15 Increase of 27% (+3.3 MNOK) 10 Molecular Tools (Research & Diagnostics) 13
Slide 12: Currency impact
Currency impact USDNOK 11 Tailwinds in currency 10,5 10 Majority of revenues are in foreign currency 9,5 73% in USD and 27% in EURO for Q3 9 8,5 USD/Euro has strenghtened towards NOK last year – 1. 1. 1. 1. 1. 1. 1. jul. 1. 1. 1. positive effect on P&L jan. feb. mar. apr. mai. jun. aug. sep. okt. Fi
Slide 13: Rolling quarterly sales development
12 month rolling average quarterly sales On track to deliver on our promises 40 Sales development 35 Sales development ex Covid-19 30 25 MNOK 20 15 10 5 0 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 13 *not reporting on Covid-19 sales separately as of Q1 2
Slide 14: Profitability and expenses
Profitability and expenses Investments in organic growth influences our figures Sales Q3 - MNOK 29.3 vs. 25.2 (+16%) YTD - MNOK 108.8 vs 87.5 (+21%) EBITDA Q3 - MNOK 2.8 vs 9.0 (-69%) YTD - MNOK 40.2 vs 40.8 (-1%) Expenses increased by 9.8 MNOK in Q3 Personnel, external support and consultancy incre
Slide 15: Cash flow
Cash flow +8 MNOK in positive cash flow for Q3 250 30 Net Cash (MNOK) 240 Changes in Cash (MNOK) 25 230 Changes in cash (MNOK) 220 20 Net Cash (MNOK) 210 200 15 190 10 180 170 5 160 150 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 15
Slide 16: Outlook
Outlook
Slide 17: Outlook 2022 and Beyond
Outlook 2022 and Beyond Annual Sale Target Remains mostly unchanged The Company outlook for 2022 70% achieved Annual sales target of NOK 155 million Quarterly fluctuations will continue Lower contribution from coronavirus-related sales Expanded innovation activities into the Oslo region Quarterly Ro
Slide 18: Thank you Q&A Session
Thank you Q&A Session arcticzymes.com